Skip to main content
SpringerLink
Log in

Monitoring Anticoagulant Therapy

  • Chapter
Laboratory Hemostasis

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of vitamin K anatogonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:204S–33S.

    Article  PubMed  CAS  Google Scholar 

  2. Coumadin, Physicians’ Desk Reference, sixtieth edition. Montvale, NJ: Thompson PDR, 2006:932–7.

    Google Scholar 

  3. World Health Organization Expert Committee on Biological Standardization. 33rd report: technical report series No. 687. Geneva, Switzerland: World Health Organization, 1983.

    Google Scholar 

  4. Critchfield GC, Bennett ST. The influence of the reference mean prothrombin time on the International Normalized Ratio. Am J Clin Pathol 1994; 102:806–11.

    PubMed  CAS  Google Scholar 

  5. Fairweather RB, Ansell J, van den Besselaar AMHP, et al. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: laboratory monitoring of oral anticoagulant therapy. Arch Pathol Lab Med 1998; 122:768–81.

    PubMed  CAS  Google Scholar 

  6. Clinical and Laboratory Standards Institute. One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline, document H47-A. Wayne, PA: CLSI, 1996.

    Google Scholar 

  7. Shahanigian S, LaBeau KM, Howerton DA. Prothrombin time testing practices: adherence to guidelines and standards. Clin Chem 2006; 52:793–4.

    Article  Google Scholar 

  8. Clinical and Laboratory Standards Institute. Procedures for Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline, document H54-A. Wayne, PA: CLSI, 2005.

    Google Scholar 

  9. van den Besselaar AM, Houbouyan-Reveillard LL. Field study of lyophilized calibrant plasmas for fresh plasma INR determination. Thromb Haemost 2002; 87:277–81.

    PubMed  Google Scholar 

  10. van den Besselaar AM, Houdijk WP. Use of lyophilized calibrant plasmas for simplified international normalized ratio determination with a human tissue factor thromboplastin reagent derived from cultured human cells. Clin Chem 2003; 49:2006–11.

    Article  PubMed  Google Scholar 

  11. Johnston M, Brigden M. A cross-Canada survey of prothrombin time testing: does the establishment of local ISI values improve the accuracy of international normalized ratio reporting? Thrombosis Interest Group of Canada. Am J Clin Pathol, 1998; 110:683–90.

    PubMed  CAS  Google Scholar 

  12. Hillarp A, Egberg N, Nordin G, et al. Local INR calibration of the Owren type prothrombin assay greatly improves the intra- and interlaboratory variation: a three-year follow-up from the Swedish national external quality assessment scheme. Thromb Haemost 2004; 91:300–7.

    PubMed  CAS  Google Scholar 

  13. Chantarangkul V, Tripodi A, Cesana BM, et al. Calibration of local systems with lyophilized calibrant plasmas improves the interlaboratory variability of the INR in the Italian external quality assessment scheme. Thromb Haemost 1999; 82:1621–6.

    PubMed  CAS  Google Scholar 

  14. Adcock DM, Johnston M. Evaluation of frozen plasma calibrants for enhanced standardization of the international normalized ratio (INR): a multi-center study. Thromb Haemost 2002; 87:74–9.

    PubMed  CAS  Google Scholar 

  15. Adcock DM, Duff S. Enhanced standardization of the International Normalized Ratio through the use of plasma calibrants: a concise review. Blood Coagul Fibrinolysis 2000; 11:583–90.

    Article  PubMed  CAS  Google Scholar 

  16. Argatroban. Physicians’ Desk Reference, sixtieth edition. Montvale, NJ:Thompson PDR, 2006:1321–25.

    Google Scholar 

  17. Refludan (lepirudin). Physicians’ Desk Reference, sixtieth edition. Montvale, NJ:Thompson PDR, 2006:815–8.

    Google Scholar 

  18. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:188S–203S.

    Article  PubMed  CAS  Google Scholar 

  19. Brummel-Ziedins K, Orfeo T, Jenny NS, et al. Blood coagulation and fibrinolysis. In: Greer JP, Rodgers GM, Foerster J, et al, editors. Wintrobe’s clinical hematology, eleventh edition. Philadelphia:Lippincott Williams & Wilkins, 2004:677–774.

    Google Scholar 

  20. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:311S–37S.

    Article  PubMed  CAS  Google Scholar 

  21. van Cott EM, Laposata M. Coagulation, fibrinolysis, and hypercoagulation. In: Henry JB, editor. Clinical diagnosis and management by laboratory methods, twentieth edition. Philadelphia:W.B. Saunders Co., 2001:642–59.

    Google Scholar 

  22. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122:782–98.

    PubMed  CAS  Google Scholar 

  23. Bosch YP, Ganushchak YM, de Jong DS. Comparison of ACT point-of-care measurements: repeatability and agreement. Perfusion 2006; 21:27–31.

    Article  PubMed  CAS  Google Scholar 

  24. Machin D, Devine P. The effect of temperature and aprotinin during cardiopulmonary bypass on three different methods of activated clotting time measurement. J Extra Corpor Technol 2005; 37:265–71.

    PubMed  Google Scholar 

  25. Paniccia R, Fedi S, Carbonetto F, et al. Evaluation of a new point-of-care celite-activated clotting time analyzer in different clinical settings: the i-STAT celite-activated clotting time test. Anesthesiology 2003; 99:54–9.

    Article  PubMed  CAS  Google Scholar 

  26. van den Besselaar AM, Meeuwisse-Braun J, Bertina RM. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost 1990; 63:16–23.

    PubMed  Google Scholar 

  27. Smythe MA, Koerber JL, Westly S, et al. Different heparin lot numbers, does it matter? Arch Pathol Lab Med 2001; 125:1458–62.

    PubMed  CAS  Google Scholar 

  28. Laposata M, Breen D, van Cott EM, et al. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122:799–807.

    PubMed  CAS  Google Scholar 

  29. Enoxaparin (low-molecular weight heparin). Physicians’ Desk Reference, sixtieth edition. Montvale, NJ:Thompson PDR, 2006:2931–7.

    Google Scholar 

  30. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:265S–86S.

    Article  PubMed  CAS  Google Scholar 

  31. Arixtra (fondaparinux). Physicians’ Desk Reference, sixtieth edition. Montvale, NJ:Thompson PDR, 2006:1325–31.

    Google Scholar 

  32. Angiomax (bivalirudin). Physicians’ Desk Reference, sixtieth edition. Montvale, NJ:Thompson PDR, 2006:1856–9.

    Google Scholar 

  33. Xigris (drotrecogin alfa activated). Physicians’ Desk Reference, sixtieth edition. Montvale, NJ:Thompson PDR, 2006:1796–8.

    Google Scholar 

  34. Barton P, Kalil AC, Nadel S, et al. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics 2004; 113:7–17.

    Article  PubMed  Google Scholar 

  35. Gosselin RC, Dager WE, King JH, et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin and argatroban, on prothrombin time and INR values. Am J Clin Pathol 2004; 121:593–9.

    Article  PubMed  CAS  Google Scholar 

  36. Gosselin RC, King JH, Janatpur KA, et al. Effects of pentasaccharide (Fondaparinux) and direct thrombin inhibitors on coagulation testing. Arch Pathol Lab Med 2004; 128:1142–5.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Sterling T. Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Catherine Thompson B.S., MT (ASCP) Robert C. Blaylock M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bennett, S.T. (2007). Monitoring Anticoagulant Therapy. In: Thompson, C., Blaylock, R.C. (eds) Laboratory Hemostasis. Springer, Boston, MA. https://doi.org/10.1007/0-387-36840-X_10

Download citation

  • DOI: https://doi.org/10.1007/0-387-36840-X_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-36838-2

  • Online ISBN: 978-0-387-36840-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation